key: cord-0716665-y3yc5r2m authors: Kumar, V.; Ghosh, K.; Chandran, A.; Panwar, S.; Bhat, A.; Konaje, S.; Das, S.; S, S.; Jaganathan, L.; Prasad, S.; D B, V.; C, S.; P R, K.; BHAT, N. title: Multicentric Evaluation of a Novel Point of Care Electrochemical ELISA Platform for SARS-CoV-2 Specific IgG and IgM Antibody Assay date: 2021-05-07 journal: nan DOI: 10.1101/2021.05.04.21256472 sha: d6ea0cb96bb6e7fee5820a565dc865d6f7dfe20c doc_id: 716665 cord_uid: y3yc5r2m New diagnostics technologies for the efficient detection and quantification of SARS-CoV-2 Antibodies is very crucial to manage the COVID-19 pandemic, especially in the context of emerging vaccination paradigms. Herein, we report on a novel point-of-care Electrochemical ELISA platform with disposable screen printed electrodes functionalized with SARS-CoV-2 Spike Glycoprotein S1, to enable fast and accurate quantitative estimation of total antibody concentration (IgG and IgM) in clinical samples. The quantification is performed with a comparison of electrochemical redox current against the current produced by the spiked monoclonal antibodies with known concentration. The assay is validated through multicentric evaluation against 3 different FDA authorized Laboratory standard techniques, using both EDTA whole blood and serum samples. We demonstrate that the proposed assay has excellent sensitivity and specificity, making it a suitable candidate for epidemiological surveys and quantification of antibodies in COVID-19 vaccination programs. The COVID-19 pandemic, resulting from the SARS-CoV-2 coronavirus has impacted the 34 entire world in an unprecedented manner. Since its identification in December 2019, the 35 pandemic has affected more than 130 million people worldwide, causing 2.9 million fatalities. 36 With the second wave of the disease crippling the world currently, newer and efficient 37 diagnostics technologies become essential in managing the disease. In this context, serological Since the introduction of serology tests reported in early 2020, there has been a lot of progress 45 in different technologies used for the detection of SARS-CoV-2 specific IgG/IgM antibodies. 46 Almost all the assays primarily target either Spike protein (S1/S2), Nucleoprotein (N) or 47 Specific Receptor Binding Domains (RBD) of SARS-CoV-2, thus enabling specificity [4] . 48 Many studies have been reported in the literature to compare the efficacies of various COVID-49 19 antibody kits [5] [6] [7] . The commercial point-of-care serological tests are primarily based on 50 lateral flow assays [8] . While these are convenient, they are qualitative at best, and require 51 manual intervention for the interpretation of colorimetry results. Liu care SARS-CoV-2 serology tests, especially given the success of electrochemical glucose 57 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. authorized Laboratory standard techniques namely Siemens COV2T S1RBD assay, DiaSorin 72 LIAISON® SARS-CoV-2 S1/S2 IgG assay and Vitros CoV2G IgG assay. All the SARS-CoV-2 related reagents were procured from The Native Antigen Company, UK. This includes the immunoreceptor used in the assay which is SARS-CoV-2 Spike Glycoprotein 76 (S1) terminally tagged with a predominantly monomeric Sheep Fc-Tag (produced in HEK293 Anti-SARS-CoV-2 Spike (S1) Antibody and Human recombinant monoclonal IgG1 Anti-80 SARS-CoV-2 Spike (S1) Antibody. In addition Goat anti Human IgG from the same vendor 81 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 7, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 7, 2021. ; https://doi.org/10.1101/2021.05.04.21256472 doi: medRxiv preprint Drugs Standard Control Organisation (CDSCO). The samples tested in one of the laboratory 106 analyzers, were also tested using electrochemical ELISA on the same day, but no later than one 107 week's time. Serum samples were stored in deep freezer, when they had to be tested beyond the 108 day of the collection, while EDTA whole blood samples were used within 24 hours of collection. Serum samples were allowed to thaw and stabilize to room temperature just before performing 110 the electrochemical ELISA test. The electrochemical ELISA test is performed by mixing 10 L of sample (EDTA whole blood 118 We use the SARS-CoV-2 S1 Spike Glycoprotein conjugated with Horse Radish Peroxidase as 119 the electrochemically active immunoreceptor (Antigen) in this ELISA assay. A very small 120 volume (6 L) of 120 nM concentration of immunoreceptor, dissolved in phosphate buffer 121 saline/stabilcoat solution is dispensed on the printed carbon working electrodes of the 122 disposable test strips (Fig. 1a) . The hand held electrochemical workstation, anuPath TM (Fig. 123 1b) is programmed to perform highly sensitive square wave voltammetry measurement to 124 obtain the faradaic redox current from the immunoreceptor. Fig. 1c illustrates the typical 125 reduction current peak obtained from the Antigen in NaCl buffer. When the buffer is spiked 126 with 300nM of SARS-CoV-2 specific antibody (IgG and IgM), the reduction current peak 127 decreases as shown in Fig. 1c . This decrease is due to the fact that the specific antigen-antibody 128 binding results in lower concentration of free antigen available for producing the redox current. 129 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 7, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is positive/negative for SARS-CoV-2 specific antibodies. In order to ensure that the assay 181 achieves 100% specificity, the threshold current was set to a value corresponding to 20nM 182 antibody concentration. Table 1 summarizes the results from this study. A total of 460 samples 183 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 7, 2021. ; https://doi.org/10.1101/2021.05.04.21256472 doi: medRxiv preprint were evaluated, of which 252 were EDTA whole blood samples and 198 were sera samples. The anuPath TM electrochemical ELISA assay achieved excellent correlation with FDA 185 authorized lab analyzers, with sensitivity and specificity of 100%. 186 Table 1 Performance evaluation of anuPath TM Electrochemical ELISA Analyzer (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 206 We demonstrate the efficacy of a novel point-of-care electrochemical ELISA assay through 207 multi-centric evaluation for the detection and quantification of SARS-CoV-2 specific 208 antibodies. The assay uses carbon screen printed electrodes on a disposable test strip, 209 functionalized with SARS-CoV-2 Spike Glycoprotein (S1) C terminally tagged with a Sheep (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 7, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 7, 2021. ; https://doi.org/10.1101/2021.05.04.21256472 doi: medRxiv preprint Head-to-head 253 comparison of two rapid high-throughput automated electrochemiluminescence immunoassays 254 targeting total antibodies to the SARS-CoV-2 nucleoprotein and spike protein receptor binding 255 domain An evaluation of 4 commercial assays for the detection of 257 SARS-CoV-2 antibodies in a predominantly mildly symptomatic low prevalence Australian 258 population Comparison of SARS-CoV-2 serological tests with different antigen 260 targets Comparative evaluation of SARS-CoV-2 IgG assays in India Evaluation of Serological SARS-CoV-2 Lateral Flow Assays for Rapid Point-of-Care Testing COVID-19 Antibody Tests and Their Limitations The potential application of electrochemical biosensors in 268 the COVID-19 pandemic: A perspective on the rapid diagnostics of SARS-CoV-2 Paper-based electrochemical biosensor for diagnosing COVID-271 19: Detection of SARS-CoV-2 antibodies and antigen Application of a nanotechnology-based, point-of-care diagnostic 274 device in diabetic kidney disease No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted Creatinine-Iron Complex and its Use in Electrochemical 276 Measurement of Urine Creatinine Aza-heterocyclic Receptors for Direct Electron Transfer 278 No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted